Xencor, Inc Cash and Cash Equivalents, Period Increase (Decrease)
Xencor, Inc (XNCR) reported Cash and Cash Equivalents, Period Increase (Decrease) of $235.04 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-07.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-05-07
- Xencor, Inc cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was $235.04M.
- Xencor, Inc cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $2.89M.
- Xencor, Inc cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $2.41M, a 65.07% decline year-over-year.
- Xencor, Inc cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$2.34M.
- Xencor, Inc cash and cash equivalents, period increase (decrease) for fiscal 2017 was $2.00M, a 3.20% increase from fiscal 2016.
- Xencor, Inc cash and cash equivalents, period increase (decrease) for fiscal 2016 was $1.94M.
- Xencor, Inc cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$42.06M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $235.04M 10-Q · filed 2018-05-07 | $237.94M derived: sum of 2 quarters · filed 2018-05-07 | $240.35M derived: sum of 3 quarters · filed 2018-05-07 | $238.01M derived: sum of 4 quarters · filed 2018-05-07 |
| 2017-12-31 | $2.89M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $5.31M derived: sum of 2 quarters · filed 2018-02-28 | $2.97M derived: sum of 3 quarters · filed 2018-02-28 | $2.00M 10-K · filed 2018-02-28 |
| 2017-09-30 | $2.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $73.00K derived: sum of 2 quarters · filed 2017-11-08 | -$894.00K 10-Q · filed 2017-11-08 | -$1.15M derived: sum of 4 quarters · filed 2018-05-07 |
| 2017-06-30 | -$2.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | -$3.31M 10-Q · filed 2017-08-07 | -$3.57M derived: sum of 3 quarters · filed 2018-05-07 | $3.34M derived: sum of 4 quarters · filed 2018-05-07 |
| 2017-03-31 | -$967.00K 10-Q · filed 2018-05-07 | -$1.23M derived: sum of 2 quarters · filed 2018-05-07 | $5.68M derived: sum of 3 quarters · filed 2018-05-07 | |
| 2016-12-31 | -$259.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $6.65M derived: sum of 2 quarters · filed 2018-02-28 | $1.94M 10-K · filed 2018-02-28 | |
| 2016-09-30 | $6.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $2.20M 10-Q · filed 2017-11-08 | ||
| 2016-06-30 | -$4.71M 10-Q · filed 2017-08-07 | |||
| 2015-12-31 | -$42.06M 10-K · filed 2018-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |